p-bromophenacyl ether | 106877-60-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-bromophenacyl ether
• 英文别名: 1-(4-Bromophenyl)-2-[2-(4-bromophenyl)-2-oxoethoxy]ethanone
• CAS: 106877-60-5
• 化学式: C₁₆H₁₂Br₂O₃
• 分子量: 412.077
• InChiKey: ZKMQTXLYCBRSMV-UHFFFAOYSA-N

物化性质

• 沸点：
  508.3±50.0 °C(Predicted)
• 密度：
  1.634±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丹皮酚 、 p-bromophenacyl ether 在 叔丁基过氧化氢 、 copper(l) iodide 作用下， 以 癸烷 、 二甲基亚砜 为溶剂， 反应 20.0h， 以53%的产率得到2-acetyl-5-methoxyphenyl 4-bromobenzoate
  参考文献：
  名称：

  铜催化含醚的2-酰基酚和1,3-二羰基化合物的氧化C–O键形成：直接接触酚酯和烯醇酯

  摘要：

  描述了2-羰基取代的苯酚和1，3-二羰基化合物与各种各样的二苄基或二烷基醚的铜催化的氧化偶联。该方案以高收率和高化学选择性提供了酚酯和烯醇酯的有效制备方法。该方法代表了经典酯化反应的替代方案。

  DOI：

  10.1021/jo500576x

文献信息

• [EN] COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
  申请人：INTOCELL INC

  公开号：WO2019008441A1

  公开（公告）日：2019-01-10

  Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

  提供了一种包括可切割连接物的化合物，其用途，以及用于制备该化合物的中间体化合物，更具体地，本发明的包括可切割连接物的化合物可能包括具有特定功能或活性的活性剂（例如，药物，毒素，配体，用于检测的探针等），能够选择性释放活性剂的SO2官能团，以及通过外部刺激触发化学反应，物理化学反应和/或生物反应的官能团，并且还可以包括具有与所需靶受体结合特异性的配体（例如，寡肽，多肽，抗体等）。
• Novel heterocyclic compound and medicinal use thereof
  申请人：——

  公开号：US20040220215A1

  公开（公告）日：2004-11-04

  The novel heterocyclic compound of the present invention is a novel heterocyclic compound having the formula (I) 1 Y: 2 wherein R 1 is H or C 1-6 alkyl, R 2 is H, —CO—C(R 4 )═C(R 4 )—R 5 wherein R 4 is H or C 1-4 alkyl, and R 5 is C 4-8 alkyl, C 2-8 alkenyl and the like, and the like, Y is the following group wherein X is O or S, R 7 is the same as R 4 , R 8 is R 10 —C(R 9 )═C(R 9 )— wherein R 9 is the same as R 4 , R 10 is C 3-6 alkyl and the like, and the like, R 14 is the same as R 4 , and R 15 is aryl and the like, Y—(CH 2 )n-O— is bonded to the 6- or 7-position of the tetrahydroisoquinoline skeleton, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases or an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环化合物是一种具有以下式子(I)1Y:2的新型杂环化合物，其中R1为H或C1-6烷基，R2为H，-CO-C(R4)═C(R4)-R5，其中R4为H或C1-4烷基，R5为C4-8烷基、C2-8烯基等，Y为以下基团，其中X为O或S，R7与R4相同，R8为R10-C(R9)═C(R9)-，其中R9与R4相同，R10为C3-6烷基等，R14与R4相同，R15为芳基等，Y-(CH2)n-O-与四氢异喹啉骨架的6-或7-位结合，n为1到4的整数，或其药学上可接受的盐。本发明的化合物(I)可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐受改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、PPAR介导疾病的预防或治疗剂或综合征X的预防或治疗剂。
• Novel indoline compound and medicinal use thereof
  申请人：Kamiya Shouji

  公开号：US20060128787A1

  公开（公告）日：2006-06-15

  The present invention provides an indoline compound represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing this indoline compound or a pharmaceutically acceptable salt thereof. The compound of the present invention shows superior ACAT inhibitory effect and superior lipoperoxidation inhibitory effect and is useful as an ACAT inhibitor or a lipoperoxidation inhibitor.

  本发明提供了一种由式(I)表示的吲哚啉化合物，其中每个符号如描述中所定义，或其药学上可接受的盐，并且含有该吲哚啉化合物或其药学上可接受的盐的制药组合物。本发明的化合物显示出优越的ACAT抑制作用和优越的脂质过氧化抑制作用，并且可用作ACAT抑制剂或脂质过氧化抑制剂。
• Novel heterocyclic derivatives and medicinal use thereof
  申请人：——

  公开号：US20040180924A1

  公开（公告）日：2004-09-16

  The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I′) 1 wherein R 1 is a hydrogen atom or C 1-6 alkyl, R 2 is —CO—C(R 4 )═C(R 4 )—R 5 wherein R 4 is a hydrogen atom or C 1-4 alkyl, and R 5 is C 4-8 alkyl, C 2-8 alkenyl, aryl or aromatic heterocycle, —CO—C≡C—R 6 wherein R 6 is C 1-8 alkyl and the like, R 3 is a hydrogen atom or C 1-4 alkyl, X is an oxygen atom or a sulfur atom, R 20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I′) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环衍生物是一种具有公式（I'）的新型杂环衍生物，其中R1是氢原子或C1-6烷基，R2是—CO—C(R4)═C(R4)—R5，其中R4是氢原子或C1-4烷基，R5是C4-8烷基、C2-8烯基、芳香族或芳香族杂环，—CO—C≡C—R6，其中R6是C1-8烷基等，R3是氢原子或C1-4烷基，X是氧原子或硫原子，R20是可选取代的苯基，n是1到4的整数，或其药学上可接受的盐。本发明的化合物（I'）可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、预防或治疗PPAR介导的疾病的药剂和预防或治疗X综合征的药剂。
• Nuclear receptor binding agents
  申请人：Dalton James T.

  公开号：US20090030036A1

  公开（公告）日：2009-01-29

  The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.

  本发明涉及一种新型的核受体结合剂（NRBAs）。这些NRBAs适用于预防和/或治疗各种疾病和病症，包括预防和治疗癌症（如前列腺癌和乳腺癌）、骨质疏松症、激素相关疾病、炎症性疾病、氧化应激相关疾病（如帕金森病和中风）、神经系统疾病、眼科疾病、心血管疾病和肥胖症。